APP and Alzheimer disease: If Olfm1 does trans-synaptically tether AMPA receptors to APP in vivo, this could potentially have implications for Alzheimer’s disease, as mutations affecting the proteolytic processing of APP (both in APP itself and its secretases) are well-known to cause early-onset Alzheimer’s disease [68, 69], the early phase of which is characterised by a loss of AMPA receptors and synaptic malfunctioning [70–72].